Atlas Trials

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT07122609 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07122609
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed and Refractory DLBCL
Start date
2025-08-05
Primary completion
2026-08-15
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.